Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2003 Sep;80(3):416–427. doi: 10.1093/jurban/jtg053

Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users

Frederick L Altice 1,✉, Sandra Springer 1, Marta Buitrago 1, David P Hunt 1, Gerald H Friedland 1
PMCID: PMC3455979  PMID: 12930880

Abstract

The introduction of highly active antiretroviral therapy (HAART) has resulted in marked reductions in mortality and acquired immunodeficiency syndrome (AIDS) incidence across all risk groups; however, the proportionate decrease among injecting drug users (IDUs) has been less impressive. Much of the disparity in benefit to IDUs has been a consequence of decreased access to and receipt of potent antiretroviral combinations. Strategies to increase access to and utilization of HAART have included entry into drug treatment and abstinence. Unfortunately, as few as 15%–20% of active drug users in the United States, and in many other countries, are in drug treatment at any one time. We report a pilot project among out-of-drug treatment IDUs infected with human immunodeficiency virus (HIV); HIV therapy was successfully provided to active heroin injectors using the Community Health Care Van (CHCV) at sites of needle exchange. Subjects were willing to initiate, but were not receiving, recommended HIV therapy and were not interested in formal drug treatment. Antiretroviral therapy regimens were selected and linked to heroin injection timing. Weekly visits were scheduled by CHCV staff to assess adverse side effects and encourage adherence. Of the 13 participants, the mean baseline HIV-1 RNA level and CD4 lymphocyte count were 162,369 (log 5.21) copies per milliliter and 265 cells per milliliter, respectively. By 6 months, the proportion whose HIV-1 RNA was below the limits of detection (<400 copies/mL) was 85% (N=11); 77% (N=10) had nondetectable levels by 9 months. By 12 months, 54% (N=7) had a persistently nondetectable viral load, and the net increase in CD4 lymphocyte count was 150 cells per milliliter. As an additional and unintended benefit of this pilot project, 9 (69%) subjects chose to enter drug treatment after achieving a nondetectable viral load. Entry into drug treatment was associated with durability of viral suppression. This small pilot study suggests that health services based on needle exchange may enhance access to HAART among out-of-treatment HIV-infected IDUs. In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention.

Keywords: Adherence, Antiretroviral therapy, Directly observed therapy, Health care, Injecting drug users, Intervention, HIV/AIDS, HIV therapeutics, Needle exchange, Substance abuse, Substance abuse treatment

Full Text

The Full Text of this article is available as a PDF (120.2 KB).

References

  • 1.Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. doi: 10.1056/NEJM196301242680405. [DOI] [PubMed] [Google Scholar]
  • 2.Update: trends in AIDS incidence—United States. MMWR Morb Mortal Wkly Rep. 1996;46:861–867. [PubMed]
  • 3.Whitman S, Murphy J, Cohen M, et al. Marked declines in HIV related mortality in Chicago in women, African Americans, Hispanics, young adults, and IDU’s, from 1995 through 1997. Arch Intern Med. 2000;160:365–369. doi: 10.1001/archinte.160.3.365. [DOI] [PubMed] [Google Scholar]
  • 4.Bamberger JD, Unick J, Klein P, et al. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health. 2000;90:699–701. doi: 10.2105/AJPH.90.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ferrando SJ, Wall TL, Batki SL, et al. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475–487. doi: 10.3109/00952999609001674. [DOI] [PubMed] [Google Scholar]
  • 6.Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495–502. doi: 10.1016/0002-9343(92)90746-X. [DOI] [PubMed] [Google Scholar]
  • 7.Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665–1670. doi: 10.3201/eid0303.970322. [DOI] [PubMed] [Google Scholar]
  • 8.Wall TL, Sorensen JL, Batki SL, et al. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995;37:261–269. doi: 10.1016/0376-8716(94)01080-5. [DOI] [PubMed] [Google Scholar]
  • 9.Muma RD, Ross MW, Parcel GS, et al. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7:439–447. doi: 10.1080/09540129550126399. [DOI] [PubMed] [Google Scholar]
  • 10.Williams A, Friedland GH. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9(7):51–54. [PubMed] [Google Scholar]
  • 11.Williams AB, Friedland GH. Substance abuse issues in women with HIV. In: Cotton DJ, Watts DH, editors. Medical Management of AIDS in Women. New York, NY: John Wiley and Sons; 1996. pp. 437–453. [Google Scholar]
  • 12.Celantano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–546. doi: 10.1001/jama.280.6.544. [DOI] [PubMed] [Google Scholar]
  • 13.Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–549. doi: 10.1001/jama.280.6.547. [DOI] [PubMed] [Google Scholar]
  • 14.O’Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med. 1994;331:450–459. doi: 10.1056/NEJM199408183310707. [DOI] [PubMed] [Google Scholar]
  • 15.Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med. 1989;111:761–763. doi: 10.7326/0003-4819-111-9-761. [DOI] [PubMed] [Google Scholar]
  • 16.O’Connor PG, Molde S, Henry S, et al. Human immunodeficiency virus infection in injection drug users: a model for primary care. Am J Med. 1992;93:382–386. doi: 10.1016/0002-9343(92)90166-9. [DOI] [PubMed] [Google Scholar]
  • 17.Selwyn PA, Budner NS, Wasserman WC, et al. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 1993;108:492–500. [PMC free article] [PubMed] [Google Scholar]
  • 18.Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47–58. doi: 10.1097/00042560-200109010-00008. [DOI] [PubMed] [Google Scholar]
  • 19.Dixon PS, Flanigan TP, DeBuono BA, et al. Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. Am J Med. 1993;95:629–635. doi: 10.1016/0002-9343(93)90359-W. [DOI] [PubMed] [Google Scholar]
  • 20.Mostashari F, Riley E, Selwyn PA, et al. Acceptance and adherence of antiretroviral therapy among HIV infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:341–348. doi: 10.1097/00042560-199808010-00005. [DOI] [PubMed] [Google Scholar]
  • 21.Heimer R, Kaplan EH, O’Keefe E, et al. Three years of needle exchange in New Haven: what have we learned? AIDS Public Policy J. 1994;9:59–74. [Google Scholar]
  • 22.Barry M, Fleck E, Lentz S, Bell C, O’Connor P, Horwitz R. “Medicine on wheels”: an opportunity for outreach and housestaff education. Conn Med. 1994;58:535–539. [PubMed] [Google Scholar]
  • 23.Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962–1969. doi: 10.1001/jama.277.24.1962. [DOI] [PubMed] [Google Scholar]
  • 24.Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16:83–88. doi: 10.1111/j.1525-1497.2001.00122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Murri R, Fantoni M, Borgo C, et al. Intravenous drug user, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:461–466. doi: 10.1097/00126334-199912150-00006. [DOI] [PubMed] [Google Scholar]
  • 26.Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–259. doi: 10.1097/00126334-200107010-00006. [DOI] [PubMed] [Google Scholar]
  • 27.Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305–2315. doi: 10.1001/jama.281.24.2305. [DOI] [PubMed] [Google Scholar]
  • 28.Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS. 1999;13:2547–2554. doi: 10.1097/00002030-199912240-00008. [DOI] [PubMed] [Google Scholar]
  • 29.Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the Euro SIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369–378. doi: 10.1097/00126334-199912010-00008. [DOI] [PubMed] [Google Scholar]
  • 30.Cheever LW, Wu AW. Medication adherence among HIV-infected patients: understanding the complex behavior of patients taking this complex therapy. Curr Infect Dis Rep. 1999;1:401–407. doi: 10.1007/s11908-999-0049-8. [DOI] [PubMed] [Google Scholar]
  • 31.Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26:195–205. doi: 10.1081/ADA-100100600. [DOI] [PubMed] [Google Scholar]
  • 32.Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115–1123. doi: 10.1097/00002030-200106150-00006. [DOI] [PubMed] [Google Scholar]
  • 33.Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA. 1998;280:567–568. doi: 10.1001/jama.280.6.567. [DOI] [PubMed] [Google Scholar]
  • 34.Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis. 1999;28:643–676. doi: 10.1086/515179. [DOI] [PubMed] [Google Scholar]
  • 35.Murray JS, Elashoff MR, Iacono-Connors LC, et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797–804. doi: 10.1097/00002030-199905070-00008. [DOI] [PubMed] [Google Scholar]
  • 36.The AVANTI Steering Committee Analysis of HIV-1 clinical trials: statistical magic? Lancet. 1999;353:2061–2064. doi: 10.1016/S0140-6736(98)10391-4. [DOI] [PubMed] [Google Scholar]
  • 37.Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511–518. doi: 10.1086/338400. [DOI] [PubMed] [Google Scholar]
  • 38.Mitty JA, Stone VE, Sands M, et al. Directly Observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 2002;34:984–990. doi: 10.1086/339447. [DOI] [PubMed] [Google Scholar]
  • 39.Babudieri S, Aceti A, D’Offizi GP, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284:179–180. doi: 10.1001/jama.284.2.179. [DOI] [PubMed] [Google Scholar]
  • 40.Fischl M, Rodriguez, A, Scerpella R, et al. Impact of directly observed therapy on outcomes in HIV clinical trials. In: Conference on Retroviruses and Opportunistic Infections; January 30–February 2, 2000; San Francisco, CA. Abstract 71.
  • 41.Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87. doi: 10.7326/0003-4819-131-2-199907200-00002. [DOI] [PubMed] [Google Scholar]
  • 42.Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863–868. doi: 10.1016/S0140-6736(99)01122-8. [DOI] [PubMed] [Google Scholar]
  • 43.Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS. 2000;14:1545–1552. doi: 10.1097/00002030-200007280-00010. [DOI] [PubMed] [Google Scholar]
  • 44.Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Resp J. 1998;12:967–971. doi: 10.1183/09031936.98.12040967. [DOI] [PubMed] [Google Scholar]
  • 45.Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health. 1999;76:468–480. doi: 10.1007/BF02351504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Clarke S, Keenan E, Ryan M, et al. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Reader. 2002;12:305–307. [PubMed] [Google Scholar]
  • 47.Mitty JA, McKenzie M, Stenzel M, Flanigan T, Carpenter CC. Modified directly observ therapy for treatment of human immunodeficiency virus. JAMA. 1999;282:1334–1334. doi: 10.1001/jama.282.14.1334. [DOI] [PubMed] [Google Scholar]
  • 48.Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30. doi: 10.7326/0003-4819-133-1-200007040-00004. [DOI] [PubMed] [Google Scholar]
  • 49.Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417–1423. doi: 10.1086/323201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Daar ES, Cohen C, Remien R, et al. Improving adherence to antiretroviral therapy. AIDS Reader. 2003;13:81–90. [PubMed] [Google Scholar]
  • 51.McPherson-Baker S, Malow RM, Penedo F, et al. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12:399–404. doi: 10.1080/09540120050123792. [DOI] [PubMed] [Google Scholar]
  • 52.Malow RM, McPherson S, Klimas N, et al. Alcohol and drug abuse: adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv. 1998;49:1021–1024. doi: 10.1176/ps.49.8.1021. [DOI] [PubMed] [Google Scholar]
  • 53.Pollard RB. Can HIV infection be treated successfully with a once-daily regimen? AIDS Reader. 2002;12:489–500. [PubMed] [Google Scholar]
  • 54.Liebman J, Lamberti M, Altice F. Effectiveness of a mobile medical van in providing screening services for STDs and HIV. Public Health Nurs. 2002;19(5):345–353. doi: 10.1046/j.1525-1446.2002.19504.x. [DOI] [PubMed] [Google Scholar]
  • 55.Pollack HA, Khoshnood K, Blankenship KM, et al. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med. 2002;17:341–348. doi: 10.1046/j.1525-1497.2002.10663.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Leidy NK. Operationalizing Maslow’s theory: development and testing of the basic need satisfaction inventory. Issues Ment Health Nurs. 1994;15:277–295. doi: 10.3109/01612849409009390. [DOI] [PubMed] [Google Scholar]
  • 57.Craig RJ, Olson RE. Differences in psychological need hierarchy between program completers and dropouts from a drug abuse treatment program. Am J Drug Alcohol Abuse. 1988;14:89–96. doi: 10.3109/00952998809001537. [DOI] [PubMed] [Google Scholar]
  • 58.Acton GJ, Malathum P. Basic need status and health-promoting self-care behavior in adults. West J Nurs Res. 2000;22:796–811. doi: 10.1177/01939450022044764. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES